Your browser doesn't support javascript.
SARS CoV-2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine Based PrEP in 2020 – A Sub-study of ANRS PREVENIR and INSERM SAPRIS-Sero Cohorts
Open forum infectious diseases ; 2022.
Article in English | EuropePMC | ID: covidwho-1823878
ABSTRACT
The potential preventive efficacy of tenofovir/emtricitabine on SARS-CoV-2 infection was assessed in HIV pre-exposition prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 IgG between May and October 2020 was similar in PrEP users and in a matched population-based cohort suggesting that tenofovir/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition.
Search on Google
Collection: Databases of international organizations Database: EuropePMC Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: Open forum infectious diseases Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: EuropePMC Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: Open forum infectious diseases Year: 2022 Document Type: Article